HomepageMedicineMerck Obtains Global License for Hansoh’s HS-10535 Medicine Merck Obtains Global License for Hansoh’s HS-10535 admin Posted on December 23, 2024 The molecule is an investigational pre-clinical oral GLP-1 receptor agonist. LEAVE A RESPONSE Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. admin View all posts Post navigation Previous PostAsk Dr. Paola – Monday December 23, 2024 Next PostWill There Ever Be Real Size Diversity in Fashion? You Might Also Like Medicine Pharmaceutical Executive: May 2024 Issue (PDF) admin May 15, 2024 Medicine FDA Approves Takeda's Gammagard Liquid for Chronic Inflammatory Demyelinating Polyneuropathy admin January 31, 2024 Medicine Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines admin January 10, 2024 Medicine Virtual Therapeutics, Akili Interactive Strike Definitive Merger Agreement Seeking to Improve Mental Health Through Immersive Video Games admin June 2, 2024
Medicine FDA Approves Takeda's Gammagard Liquid for Chronic Inflammatory Demyelinating Polyneuropathy admin January 31, 2024
Medicine Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines admin January 10, 2024
Medicine Virtual Therapeutics, Akili Interactive Strike Definitive Merger Agreement Seeking to Improve Mental Health Through Immersive Video Games admin June 2, 2024